Drugs / KSV01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07246707 | Jan 2026 → Oct 2027 expected | — | Zhejiang University | Recruiting | No outcome recorded |
| Phase 1 | NCT07260812 | Sep 2025 → Dec 2028 expected | diffuse large B-cell lymphoma | TCRx Therapeutics Co.Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSV01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07246707 ↗ |
| Target | CD19 | “carries CD19 CAR” NCT07246707 ↗ |